Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 1.00 |
| ▸ | PIM1 | P11309 | 2/20 | 0.54 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.51 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177329 | 1.00 | PPARG (1.00) | PPARGPIM1PIM2HDAC4HDAC8 | |
| SCHEMBL12520491 | 1.00 | PPARG (1.00) | PPARGPIM1PIM2HDAC4HDAC8 | |
| SCHEMBL12521900 | 0.95 | PPARG (0.91) | PPARGPIM1PIM2HDAC4HDAC8 | |
| SCHEMBL2177341 | 0.90 | PPARG (0.81) | PPARGHDAC4HDAC8 | |
| SCHEMBL12521729 | 0.89 | PPARG (1.00) | PPARGPIM1PIM2HDAC4HDAC8 | |
| SCHEMBL12521723 | 0.88 | PPARG (0.78) | PPARGPIM1PIM2HDAC4HDAC8 | |
| SCHEMBL2178690 | 0.85 | PPARG (0.80) | PPARGHPGD | |
| SCHEMBL1847312 | 0.85 | PPARG (0.80) | PPARGHPGD | |
| SCHEMBL1845213 | 0.83 | PPARG (0.71) | PPARGPIM1PIM2HPGDCISD1 | |
| SCHEMBL12520388 | 0.83 | PPARG (0.71) | PPARGPIM1PIM2HPGDCISD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | BEECHAM GROUP P.L.C. | 2003-08-07 | — | — | US | claimed |
| EP-1306086-A2 | Use of thiazolidinediones for the treatment of atherosclerosis and eating disorders | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | claimed |
| US-20020049240-A1 | NOVEL COMPOUNDS | BEECHAM GROUP P.1.C. | 2002-04-25 | — | — | US | claimed |
| EP-0842925-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1998-05-20 | — | — | EP | claimed |
| EP-0695183-A1 | USE OF THIAZOLIDINEDIONES FOR THE TREATMENT OF ATHEROSCLEROSIS AND EATING DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1996-02-07 | — | — | EP | claimed |
| WO-1994025026-A1 | USE OF THIAZOLIDINEDIONES FOR THE TREATMENT OF ATHEROSCLEROSIS AND EATING DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1994-11-10 | — | — | WO | claimed |
| US-5232925-A | Treating hypertension | BEECHAM GROUP P.L.C. (GB) | 1993-08-03 | — | — | US | claimed |
| US-5002953-A | Substituted Thiazolidinedione Derivatives | BEECHAM GROUP P.L.C. (GB) | 1991-03-26 | — | — | US | claimed |
| EP-0306228-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1989-03-08 | — | — | EP | claimed |
| JP-10194970-A | — | — | None | — | — | JP | disclosed |
| US-11021751-B2 | Disease risk factors and methods of use | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210095345-A1 | METHOD OF IDENTIFYING DISEASE RISK FACTORS | ZINFANDEL PHARMACEUTICALS INC (US) | 2021-04-01 | — | — | US | disclosed |
| US-20150073022-A1 | DISEASE RISK FACTORS AND METHODS OF USE | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150073025-A1 | METHOD FOR IDENTIFYING DISEASE RISK FACTORS | ZINFANDEL PHARMACEUTICALS INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-5521201-A | SUBSTITUTED-THIAZOLIDINEDIONE DERIVATIVES | BEECHAM GROUP P.L.C. | 1996-05-28 | — | — | US | disclosed |
| US-5260445-A | Hypoglycemic | BEECHAM GROUP P.L.C. (GB) | 1993-11-09 | — | — | US | disclosed |
| US-5232925-A | Treating hypertension | BEECHAM GROUP P.L.C. (GB) | 1993-08-03 | — | — | US | disclosed |
| US-5194443-A | Thiazolinediones, Hypoglycemic Agents, Antilipemic Agents | BEECHAM GROUP P.L.C. (GB) | 1993-03-16 | — | — | US | disclosed |
| US-5002953-A | Substituted Thiazolidinedione Derivatives | BEECHAM GROUP P.L.C. (GB) | 1991-03-26 | — | — | US | disclosed |
| EP-0306228-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | TYK2, FABP3, FABP4 | PPARG 16/4885PIM1 3064/4885PIM2 3068/4885 |
| US-20020049240-A1 | NOVEL COMPOUNDS | GRK1, GRK3, GRK7 | PPARG 715/4885PIM1 4286/4885PIM2 4673/4885 |
| US-20150073022-A1 | DISEASE RISK FACTORS AND METHODS OF USE | TSG101, TOMM40, TOMM70 | PPARG 1229/4885PIM1 3384/4885PIM2 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.